When comparing WT1 as an MRD marker with other monitoring techniques such as PCR for fusion gene transcripts (RUNX1::RUNX1T1, and CBFB::MYH11), similar sensitivities were observed in predicting the relapse among CBF pediatric patients with AML and failure to achieve either 3 log by PCR or 2 log by WT1 post intensification I carry a higher incidence of relapse regardless response by MFC. This evidence concerns the gene RUNX1 and acute myeloid leukemia.